WVP
APRE icon

Worth Venture Partners’s Aprea Therapeutics APRE Stock Holding History

Worth Venture Partners’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-87,169
Closed -$410K – 69
2023
Q4 		$410K Hold
87,169
– – 0.22% 78
2023
Q3 		$365K Hold
87,169
– – 0.22% 89
2023
Q2 		$275K Buy
87,169
+2,300
+3% +$8.57K 0.15% 96
2023
Q1 		$378K Buy
+84,869
New +$627K 0.18% 98

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Worth Venture Partners's APRE Position: Q1 2024 in Review

Worth Venture Partners sold out of Aprea Therapeutics (APRE) in Q1 2024, closing a stake of 87,169 shares — an estimated $410K sold.

Worth Venture Partners first reported a position in APRE in Q1 2023 and held it in 4 quarters. The position peaked at $410K in Q4 2023. 24 funds tracked by Wall St. Rank hold APRE as of Q1 2024.

  • Worth Venture Partners reported no remaining Aprea Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Worth Venture Partners sold 87,169 Aprea Therapeutics shares in Q1 2024, an estimated $410K.
  • Worth Venture Partners first reported a position in Aprea Therapeutics in Q1 2023 and held it in 4 quarters.
  • Worth Venture Partners's Aprea Therapeutics position peaked at $410K in Q4 2023.
  • 24 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2024.

Based on Worth Venture Partners's 13F filing for Q1 2024, filed 13 May 2024.